BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-κB nuclear translocation.

Purpose: Chronic lymphocytic leukemia (CLL) pathophysiology is characterized by a complex crosstalk of tumor cells with the microenvironment. In this regard, NF-kappa B signaling is considered as important signaling axis, with a variety of key molecules aberrantly expressed or genetically altered in patients with CLL. One of these molecules is BIRC3 (cIAP2), a central regulator of noncanonical NF-kappa B signaling that serves as pathway brake in the absence of microenvironmental signals. However, the contribution of BIRC3 expression to CLL progression and potential therapeutic implications is unknown. Experimental Design: We analyzed the role of BIRC3 mRNA expression in primary CLL samples in correlation to clinical datasets and used ex vivo assays to investigate functional consequences on the level of NF-kappa B signaling and downstream target gene regulation. For proof-of-principle experiments, we used genetically modified cell lines. Results: We demonstrate that patients with CLL with low BIRC3 expression experience a more rapid disease progression, which coincides with an enhanced activation of canonical NF-kappa B target genes evidenced by an increased p65/Rel-B nuclear translocation ratio. As a consequence of enhanced canonical NF-kappa B target gene activation, both anti-and proapoptotic Bcl-2 family members were upregulated in BIRC3(low) primary CLL cells, which was associated with higher sensitivity to venetoclax treatment in vitro. Conclusions: Here we show the impact of BIRC3 expression in CLL disease progression in the absence of BIRC3 mutations and show altered canonical NF-kappa B target gene activation with therapeutic implications.